Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer

We aimed to assess the relationship between bone scintigraphy findings and prostate-specific antigen (PSA) and Gleason score in a group of treatment naïve West Africans with prostate cancer. The age, PSA, and Gleason scores of 363 patients with prostate cancer were collected. Patients were risk stra...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaw Ampem Amoako, Emmanuel Nii Boye Hammond, Awo Assasie-Gyimah, Dennis Odai Laryea, Alfred Ankrah, George Amoah
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=2;spage=143;epage=148;aulast=Amoako
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850237185101398016
author Yaw Ampem Amoako
Emmanuel Nii Boye Hammond
Awo Assasie-Gyimah
Dennis Odai Laryea
Alfred Ankrah
George Amoah
author_facet Yaw Ampem Amoako
Emmanuel Nii Boye Hammond
Awo Assasie-Gyimah
Dennis Odai Laryea
Alfred Ankrah
George Amoah
author_sort Yaw Ampem Amoako
collection DOAJ
description We aimed to assess the relationship between bone scintigraphy findings and prostate-specific antigen (PSA) and Gleason score in a group of treatment naïve West Africans with prostate cancer. The age, PSA, and Gleason scores of 363 patients with prostate cancer were collected. Patients were risk stratified using the D'Amico criteria. Logistic regression was performed to assess the relationship between bone scan results and PSA and Gleason score. Receiver operating characteristics (ROC) analysis was used to determine the diagnostic reliability of the bone scan findings. Ninety of the 96 patients with metastases had high risk, and only 6 had low-to-intermediate risk disease (P = 0.0001). PSA (odds ratio [OR] 2.4 [95% confidence interval [CI] 1.5–3.8], P = 0.001) and GS (OR 2.2 [95% CI 1.5–3.1], P = 0.001) were independently predictive of the presence of metastases. ROC analysis revealed that PSA predicted the presence of metastases with an area under the curve of 0.72, and using a cut-off value of ≥20 predicted metastases with a sensitivity of 86.5% and specificity of 41.2%. A Gleason score of ≥7 had an 89.6% sensitivity and 34.8% specificity for bone metastases. Using a Gleason cutoff of ≥8, the sensitivity and specificity for predicting bone metastases were 54.2% and 71.5%, respectively. The area under the Gleason score ROC curve was 0.68. PSA and Gleason score are independent predictors of the presence of bone metastases in West Africans with prostate cancer.
format Article
id doaj-art-2fa0e5a9ff1e44a18dec53a6761b8283
institution OA Journals
issn 1450-1147
language English
publishDate 2019-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series World Journal of Nuclear Medicine
spelling doaj-art-2fa0e5a9ff1e44a18dec53a6761b82832025-08-20T02:01:47ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11472019-01-0118214314810.4103/wjnm.WJNM_38_18Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancerYaw Ampem AmoakoEmmanuel Nii Boye HammondAwo Assasie-GyimahDennis Odai LaryeaAlfred AnkrahGeorge AmoahWe aimed to assess the relationship between bone scintigraphy findings and prostate-specific antigen (PSA) and Gleason score in a group of treatment naïve West Africans with prostate cancer. The age, PSA, and Gleason scores of 363 patients with prostate cancer were collected. Patients were risk stratified using the D'Amico criteria. Logistic regression was performed to assess the relationship between bone scan results and PSA and Gleason score. Receiver operating characteristics (ROC) analysis was used to determine the diagnostic reliability of the bone scan findings. Ninety of the 96 patients with metastases had high risk, and only 6 had low-to-intermediate risk disease (P = 0.0001). PSA (odds ratio [OR] 2.4 [95% confidence interval [CI] 1.5–3.8], P = 0.001) and GS (OR 2.2 [95% CI 1.5–3.1], P = 0.001) were independently predictive of the presence of metastases. ROC analysis revealed that PSA predicted the presence of metastases with an area under the curve of 0.72, and using a cut-off value of ≥20 predicted metastases with a sensitivity of 86.5% and specificity of 41.2%. A Gleason score of ≥7 had an 89.6% sensitivity and 34.8% specificity for bone metastases. Using a Gleason cutoff of ≥8, the sensitivity and specificity for predicting bone metastases were 54.2% and 71.5%, respectively. The area under the Gleason score ROC curve was 0.68. PSA and Gleason score are independent predictors of the presence of bone metastases in West Africans with prostate cancer.http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=2;spage=143;epage=148;aulast=AmoakoBone scintigraphyGhanaGleason scoreprostate cancerprostate-specific antigen
spellingShingle Yaw Ampem Amoako
Emmanuel Nii Boye Hammond
Awo Assasie-Gyimah
Dennis Odai Laryea
Alfred Ankrah
George Amoah
Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
World Journal of Nuclear Medicine
Bone scintigraphy
Ghana
Gleason score
prostate cancer
prostate-specific antigen
title Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
title_full Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
title_fullStr Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
title_full_unstemmed Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
title_short Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
title_sort prostate specific antigen and risk of bone metastases in west africans with prostate cancer
topic Bone scintigraphy
Ghana
Gleason score
prostate cancer
prostate-specific antigen
url http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=2;spage=143;epage=148;aulast=Amoako
work_keys_str_mv AT yawampemamoako prostatespecificantigenandriskofbonemetastasesinwestafricanswithprostatecancer
AT emmanuelniiboyehammond prostatespecificantigenandriskofbonemetastasesinwestafricanswithprostatecancer
AT awoassasiegyimah prostatespecificantigenandriskofbonemetastasesinwestafricanswithprostatecancer
AT dennisodailaryea prostatespecificantigenandriskofbonemetastasesinwestafricanswithprostatecancer
AT alfredankrah prostatespecificantigenandriskofbonemetastasesinwestafricanswithprostatecancer
AT georgeamoah prostatespecificantigenandriskofbonemetastasesinwestafricanswithprostatecancer